The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Osteitis


High impact information on Osteitis

  • In patients with osteitis fibrosa as the predominant histological lesion, calcifediol therapy resulted in decreased calcification front activity [6].
  • The result was progressive disappearance of symptoms related to secondary hyperparathyroidism, healing of osteitis fibrosa, and normalization of serum concentrations of immunoreactive parathyroid hormone [7].
  • The hydrocortisone test was not helpful in patients with osteitis fibrosa [8].
  • Results of bone scintigrams using 99mTc-methylene diphosphonate were positive in only 7 of 15 patients (47%), with a correlation between positive uptake and osteitis [9].
  • All patients with serum calcium levels < 10.0 mg/dL and serum PTH levels > 125 pg/mL had either osteitis fibrosa or mixed bone lesions--a group of patients that might benefit from aggressive vitamin D therapy [10].

Chemical compound and disease context of Osteitis


Biological context of Osteitis

  • The 21 patients were classified by histomorphometry as follows: osteitis fibrosa, 5; mild hyperparathyroidism, 3; normal histology, 3; aplastic, 6; and mixed lesions, 4 [10].
  • Histologic bone features were compatible with osteitis fibrosa in all patients, which suggests that the skeleton responded to the bone-remodeling effects of PTH despite hormonal resistance at other target sites [16].
  • Bone regeneration is possible in peri-implant osteitis defects if appropriate surgical techniques are used [17].

Anatomical context of Osteitis


Gene context of Osteitis

  • The osteitis fibrosa cystica was presumably due to the increased PTH, suggesting that resistance to PTH was present in kidney but not bone [23].
  • Patients with severe secondary hyperparathyroidism, usually associated with osteitis fibrosa on bone histology, show considerable resistance to Epoetin, partly because of replacement of the cellular components of the bone marrow by fibrous tissue [24].
  • Diagnosis of 1 degree HPT could only be made from recurrent urolithiasis and X-ray picture of osteitis fibrosa cystica in the past [25].
  • Prominent clinical features included nephrolithiasis in 72 subjects (56%), osteitis fibrosa cystica in 2, isolated familial hyperparathyroidism in 4 subjects in one family, 7 subjects with MEN-1 in 3 families, and 4 subjects with MEN-2 in one family [26].
  • The peak of [3H]thymidine incorporation, the maximal DNA synthesis, and the area under the growth curve were 4.4- to 6.3-fold increased in osteitis fibrosa compared to those in normal bone cells obtained from age-matched individuals [27].

Analytical, diagnostic and therapeutic context of Osteitis


  1. Toxicity of parathyroid hormone in uremia. Klahr, S., Slatopolsky, E. Annu. Rev. Med. (1986) [Pubmed]
  2. Suppression of streptococcal cell wall-induced arthritis by a potent protease inhibitor, bis(5-amidino-2-benzimidazolyl)methane. Geratz, J.D., Pryzwansky, K.B., Schwab, J.H., Anderle, S.K., Tidwell, R.R. Arthritis Rheum. (1988) [Pubmed]
  3. Osteomalacia and osteitis fibrosa in a man ingesting aluminum hydroxide antacid. Carmichael, K.A., Fallon, M.D., Dalinka, M., Kaplan, F.S., Axel, L., Haddad, J.G. Am. J. Med. (1984) [Pubmed]
  4. Pseudohyperparathyroidism. Syndrome associated with aluminum intoxication in patients with renal failure. Sherrard, D.J., Ott, S.M., Andress, D.L. Am. J. Med. (1985) [Pubmed]
  5. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy. Bordier, P., Zingraff, J., Gueris, J., Jungers, P., Marie, P., Pechet, M., Rasmussen, H. Am. J. Med. (1978) [Pubmed]
  6. Calcifediol in chronic renal insufficiency. Skeletal response. Teitelbaum, S.L., Bone, J.M., Stein, P.M., Gilden, J.J., Bates, M., Boisseau, V.C., Avioli, L.V. JAMA (1976) [Pubmed]
  7. Secondary hyperparathyroidism. Conservative management in patients with renal insufficiency. Popovtzer, M.M., Pinggera, W.F., Robinette, J.B. JAMA (1975) [Pubmed]
  8. Hydrocortisone suppression test and discriminant analysis in differential diagnosis of hypercalcaemia. Watson, L., Moxham, J., Fraser, P. Lancet (1980) [Pubmed]
  9. Costochondral involvement in systemic candidiasis in heroin addicts: clinical, scintigraphic, and histologic features in 26 patients. Miro, J.M., Brancos, M.A., Abello, R., Lomena, F., Bisbe, J., Ribalta, T., Rotes-Querol, J. Arthritis Rheum. (1988) [Pubmed]
  10. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital. Mathias, R., Salusky, I., Harman, W., Paredes, A., Emans, J., Segre, G., Goodman, W. J. Am. Soc. Nephrol. (1993) [Pubmed]
  11. The effects of calciferol and its metabolites on patients with chronic renal failure. I. Calciferol, dihydrotachysterol, and calcifediol. Voigts, A.L., Felsenfeld, A.J., Llach, F. Arch. Intern. Med. (1983) [Pubmed]
  12. Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining. Hodsman, A.B., Steer, B.M. J. Am. Soc. Nephrol. (1992) [Pubmed]
  13. Vitamin D metabolism during recovery from severe osteitis fibrosa cystica of primary hyperparathyroidism. Gonzalez-Villapando, C., Porath, A., Berelowitz, M., Marshall, L., Favus, M.J. J. Clin. Endocrinol. Metab. (1980) [Pubmed]
  14. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Wada, M., Ishii, H., Furuya, Y., Fox, J., Nemeth, E.F., Nagano, N. Kidney Int. (1998) [Pubmed]
  15. Ghost infantile vertebrae and hemipelves within adult skeleton from thorotrast administration in childhood. Teplick, J.G., Head, G.L., Kricun, M.E., Haskin, M.E. Radiology. (1978) [Pubmed]
  16. Metabolic bone disease in pseudohypoparathyroidism: radiologic features. Burnstein, M.I., Kottamasu, S.R., Pettifor, J.M., Sochett, E., Ellis, B.I., Frame, B. Radiology. (1985) [Pubmed]
  17. Osteopromotion as an adjunct to osseointegration. Kenney, E.B., Jovanovic, S.A. The International journal of prosthodontics. (1993) [Pubmed]
  18. Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. Murray, T.M., Rao, L.G., Wong, M.M., Waddell, J.P., McBroom, R., Tam, C.S., Rosen, F., Levine, M.A. J. Bone Miner. Res. (1993) [Pubmed]
  19. Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Lotinun, S., Sibonga, J.D., Turner, R.T. Endocrine (2002) [Pubmed]
  20. Surgical treatment of septic pedal osteitis in horses: nine cases (1980-1987). Gaughan, E.M., Rendano, V.T., Ducharme, N.G. J. Am. Vet. Med. Assoc. (1989) [Pubmed]
  21. Spontaneous rupture of the quadriceps tendon in patients on maintenance hemodialysis--report of three cases with clinicopathological observations. Ryuzaki, M., Konishi, K., Kasuga, A., Kumagai, H., Suzuki, H., Abe, S., Saruta, T., Takami, H., Tashiro, M. Clin. Nephrol. (1989) [Pubmed]
  22. Sphenoid sinus brown tumor, hypercalcemia, and blindness: an unusual presentation of primary hyperparathyroidism. Schweitzer, V.G., Thompson, N.W., McClatchey, K.D. Head & neck surgery. (1986) [Pubmed]
  23. Renal-resistant hormonoplethoric hypoparathyroidism with evidence for a defective response to cAMP. Duck, S.C., Rosenberg, E.M., Ratzan, S.K., Haymond, M.W. J. Clin. Endocrinol. Metab. (1978) [Pubmed]
  24. Hyperparathyroidism and anemia in renal failure. Gallieni, M., Corsi, C., Brancaccio, D. American journal of nephrology. (2000) [Pubmed]
  25. A patient of primary hyperparathyroidism with full-blown bone changes simulating malignancy. Chuang, T.C., Chang, J.M., Hwang, S.J., Hsiao, P.J., Lai, Y.H. The Kaohsiung journal of medical sciences. (1998) [Pubmed]
  26. Clinical profile of 128 subjects operated for primary hyperparathyroidism. Haddock, L., Aguiló, F., Vázquez Quintana, E., Vázquez, M.C., Rabell, V., Allende, M. Puerto Rico health sciences journal. (1998) [Pubmed]
  27. Relationships between histomorphometric features of bone formation and bone cell characteristics in vitro in renal osteodystrophy. Marie, P.J., Lomri, A., de Vernejoul, M.C., Morieux, C., Graulet, A.M., Guéris, J., Llach, F. J. Clin. Endocrinol. Metab. (1989) [Pubmed]
  28. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. Andress, D.L., Norris, K.C., Coburn, J.W., Slatopolsky, E.A., Sherrard, D.J. N. Engl. J. Med. (1989) [Pubmed]
  29. Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia. Andress, D., Felsenfeld, A.J., Voigts, A., Llach, F. Kidney Int. (1983) [Pubmed]
  30. Tumor detection in extremities of man with 99mTc-tetracycline. Riihimäki, E., Suoranta, H., Tallroth, K. European journal of nuclear medicine. (1976) [Pubmed]
  31. Measurement of whole body calcium in chronic renal failure: effects of 1alpha-hydroxyvitamin D3 and parathyroidectomy. Naik, R.B., Dabek, J.T., Heynen, G., James, H.M., Kanis, J.A., Robertson, P.W., Robinson, B.H., Woods, C.G. Clin. Endocrinol. (Oxf) (1977) [Pubmed]
  32. Parathyroid hormone-like bioactivity in a patient with severe osteitis fibrosa cystica due to malignancy: renotropic actions of a tumour extract as assessed by cytochemical bioassay. Loveridge, N., Kent, G.N., Heath, D.A., Jones, E.L. Clin. Endocrinol. (Oxf) (1985) [Pubmed]
WikiGenes - Universities